Dr. Chris Baldwin is the Chief Executive Officer and Managing Director of HaemaLogiX.
Dr Rosanne Dunn is an Executive Director and the Chief Scientific Officer at HaemaLogiX, and was a Co-Founder of the Company and has been a Director since the Company's incorporation.
Dr Geoff Nichol is an Executive Director and Chief Operating Officer at Haemalogix, and was appointed a Director in June 2022.
Professor Mohamad Hussein is Chief Medical Advisor at HaemaLogiX and has held academic, clinical, and pharmaceutical leadership roles focused on hematologic malignancies, especially multiple myeloma.
Kerem Kaya is the Chief Financial Officer and Co-Company Secretary at HaemaLogiX and commenced with the Company in March 2024.
Tertia Dex has over 20 years of experience in biopharmaceutical development and manufacturing, with a strong leadership background in CDMOs.
Halley Hilton brings over 25 years of clinical and operational experience in pharmaceutical and biotech industries across multiple therapeutic areas.
Rhonda has extensive experience supporting regulatory applications, scientific communication, and international medical writing across oncology and autoimmune fields.
Dr Ben Buckley is a translational scientist with over 10 years of experience in oncology drug discovery and early-phase development.
